Get the Stockscreener App
4.77
3.84%
-0.18
After Hours:
4.54
-0.23
-4.82%
Bluebird Bio Inc stock is traded at $4.77, with a volume of 227.47K.
It is down -3.84% in the last 24 hours and up +19.00% over the past month.
See More
Previous Close:
$4.95
Open:
$4.85
24h Volume:
227.47K
Relative Volume:
0.56
Market Cap:
$47.09M
Revenue:
$21.73M
Net Income/Loss:
$-91.17M
P/E Ratio:
-6.4459
EPS:
-0.74
Net Cash Flow:
$-286.43M
1W Performance:
-2.46%
1M Performance:
+19.00%
6M Performance:
-54.28%
1Y Performance:
-80.65%
1-Day Range:
$4.61
$5.24
1-Week Range:
$4.61
$5.411
52-Week Range:
$3.56
$28.60
Bluebird Bio Inc Stock (BLUE) Company Profile
Name
Bluebird Bio Inc
Sector
Industry
Phone
339-499-9300
Address
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Compare BLUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
4.77 | 47.09M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 32.85B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 28.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-15-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-11-23 | Downgrade | HSBC Securities | Hold → Reduce |
| Dec-08-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-17-23 | Initiated | Cantor Fitzgerald | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-19-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-01-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-28-23 | Initiated | JP Morgan | Overweight |
| Mar-07-23 | Initiated | Robert W. Baird | Outperform |
| Aug-05-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-02-22 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-06-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-07-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-08-21 | Reiterated | Barclays | Equal Weight |
| Nov-08-21 | Reiterated | Canaccord Genuity | Hold |
| Nov-08-21 | Downgrade | Goldman | Neutral → Sell |
| Nov-08-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Nov-08-21 | Reiterated | Wedbush | Neutral |
| Nov-08-21 | Reiterated | Wells Fargo | Equal Weight |
| Aug-10-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-10-21 | Downgrade | Goldman | Buy → Neutral |
| Aug-10-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-10-21 | Resumed | William Blair | Mkt Perform |
| Aug-09-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Mar-10-21 | Upgrade | Mizuho | Neutral → Buy |
| Feb-17-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-16-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-16-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-09-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-05-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-05-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Nov-05-20 | Downgrade | Stifel | Buy → Hold |
| Nov-02-20 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-20-20 | Initiated | Mizuho | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-27-20 | Upgrade | Stifel | Hold → Buy |
| Feb-19-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Feb-03-20 | Resumed | BofA/Merrill | Buy |
| Feb-03-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-13-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-19-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-01-19 | Initiated | Stifel | Hold |
| Aug-12-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-19 | Upgrade | Maxim Group | Hold → Buy |
View All
Bluebird Bio Inc Stock (BLUE) Latest News
Gene Therapy Market Demand, Growth and Future Scope 2025-2032 | - openPR.com
Deal Dispatch: US M&A Is Quiet, But Abroad? Volume Is Spiking - Benzinga
Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, Avatar - MarketScreener
Xcellbio Announces Commercial Licensing & Supply Agreement to Support Commercial Production of Gene Therapy for Sickle Cell disease - Business Wire
BlueBird Shares Are Up Today: What's Going On? - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumpsbluebird bio (NASDAQ:BLUE) - Benzinga
Bluebird Bio Receives $4.50 Per Share Acquisition Proposal From Ayrmid - Nasdaq
bluebird bio’s SWOT analysis: biotech firm’s stock faces cash crunch, product potential - Investing.com
Bluebird bio rises on non-binding bid for up to $110.5 million - TradingView
Bluebird bio receives non-binding bid for up to $110.5 million - MSN
Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates - MSN
Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more - MSN
Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more (T:NYSE) - Seeking Alpha
bluebird bio confirms rival takeover bid - The Pharma Letter
Bluebird Bio Stock Leaps On Ayrmid Offer Amid Financial Strain - Finimize
Bluebird Bio Draws New Bid, Sending Shares Climbing - Finimize
Ayrmid Proposes to Acquire Bluebird Bio, Inc. (BLUE) with Premiu - GuruFocus
New suitor emerges for struggling bluebird bio - FirstWord Pharma
Bluebird Bio (BLUE) Receives Acquisition Offer from Ayrmid - GuruFocus.com
Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer - Fierce Pharma
bluebird bio (BLUE) Receives Higher Bid from Ayrmid Pharma - GuruFocus
bluebird bio sees higher offer for company from Ayrmid Pharma - Seeking Alpha
Bluebird Bio (BLUE) Receives Higher Buyout Bid from Ayrmid - GuruFocus
Bluebird gets rival takeout offer from Ayrmid - BioPharma Dive
bluebird bio receives higher acquisition offer from Ayrmid - Investing.com India
Bluebird Bio shares rally 11% in late trade on buyout offer - TradingView
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
bluebird bio receives higher acquisition offer from Ayrmid By Investing.com - Investing.com South Africa
Bluebird bio reports another acquisition offer for $45M upfront - The Business Journals
Bluebird Bio Gets Rival Buyout Proposal From Ayrmid; Shares Jump After Hours - Marketscreener.com
Bluebird bio stock rises on new acquisition proposal By Investing.com - Investing.com South Africa
Bluebird bio stock rises on new acquisition proposal - Investing.com
Bluebird Bio confirms receipt non-binding proposal from Ayrmid - TipRanks
Bluebird Bio Confirms Receipt Of An Unsolicited Non-Binding Proposal From Ayrmid - MarketScreener
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid - Business Wire
Sickle Cell Treatment Market Business Outlook and Growth - openPR
bluebird bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
T-Cell Immunotherapy Market is Booming Worldwide |Medigene,Bluebird Bio,Novartis - openPR
Sickle Cell Disease Treatment Market: New Drug Approvals - openPR
Breaking Notice: Rosen, a Globally Recognized Law Firm, Encourages bluebird bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – BLUE - Business Wire
Gene therapy loses luster as investors eye quicker returns from weight-loss drugs - Reuters
Drug developers show mixed performance in early 2025 - BioWorld Online
Sickle Cell Disease Pipeline 2025 Detailed Clinical Trials - openPR
Carlyle's bluebird Deep Discount Buyout (Rating Upgrade) - Seeking Alpha
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc.BLUE - PR Newswire
Gene therapy efforts active, despite low Bluebird, 2seventy bids - BioWorld Online
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc.BLUE - Business Wire
Gene Therapy Market Future Business Opportunities 2025-2032 | - openPR
Bluebird Bio Inc Stock (BLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):